BR0213486A - Combinações que compreendem um inibidor seletivo de ciclooxigenase-2 - Google Patents

Combinações que compreendem um inibidor seletivo de ciclooxigenase-2

Info

Publication number
BR0213486A
BR0213486A BR0213486-1A BR0213486A BR0213486A BR 0213486 A BR0213486 A BR 0213486A BR 0213486 A BR0213486 A BR 0213486A BR 0213486 A BR0213486 A BR 0213486A
Authority
BR
Brazil
Prior art keywords
inhibitor
combinations
growth factor
selective cyclooxygenase
cyclooxygenase
Prior art date
Application number
BR0213486-1A
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0213486A publication Critical patent/BR0213486A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMBINAçõES QUE COMPREENDEM UM INIBIDOR SELETIVO DE CICLOOXIGENASE-2". A presente invenção refere-se a uma terapia de combinação para tratamento de pacientes que sofrem de lesões pré-malignas do cólon (por exemplo, pólipos) e de câncer do cólon, assim como outras malignidades. O paciente é tratado concorrentemente com um inibidor de ciclooxigenase-2 e pelo menos um composto selecionado do grupo que consiste em um agente de interferência em microtúbulo, um inibidor de tirosina proteína quinase receptor de fator de crescimento epitelial e um inibidor de tirosina quinase receptor de fator de crescimento endotelial vascular.
BR0213486-1A 2001-10-25 2002-10-24 Combinações que compreendem um inibidor seletivo de ciclooxigenase-2 BR0213486A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (1)

Publication Number Publication Date
BR0213486A true BR0213486A (pt) 2005-05-10

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213486-1A BR0213486A (pt) 2001-10-25 2002-10-24 Combinações que compreendem um inibidor seletivo de ciclooxigenase-2

Country Status (22)

Country Link
US (2) US20050043409A1 (pt)
EP (1) EP1441714B1 (pt)
JP (1) JP2005506366A (pt)
KR (1) KR100954625B1 (pt)
CN (1) CN100506224C (pt)
AT (1) ATE381930T1 (pt)
AU (2) AU2006252156A1 (pt)
BR (1) BR0213486A (pt)
CA (1) CA2464309C (pt)
CY (1) CY1108045T1 (pt)
DE (1) DE60224299T2 (pt)
DK (1) DK1441714T3 (pt)
ES (1) ES2295428T3 (pt)
HU (1) HUP0600235A3 (pt)
IL (1) IL161462A0 (pt)
MX (1) MXPA04003878A (pt)
NZ (2) NZ532418A (pt)
PL (1) PL369305A1 (pt)
PT (1) PT1441714E (pt)
RU (1) RU2333754C2 (pt)
SI (1) SI1441714T1 (pt)
WO (1) WO2003035047A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
EP1660504B1 (en) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
BRPI0414698A (pt) * 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
BRPI0414604A (pt) * 2003-09-23 2006-11-07 Novartis Ag combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos
EA009994B1 (ru) 2003-12-23 2008-06-30 Пфайзер Инк. Новые хинолиновые производные
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298022B6 (cs) * 1996-10-15 2007-05-30 G. D. Searle & Co. Použití inhibitoru cyklooxygenázy-2 pro výrobu léciva pro lécení a prevenci neoplazie
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
PL353267A1 (en) * 1999-08-12 2003-11-03 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
DE60018792T2 (de) * 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
AU3822701A (en) * 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
AU778417B2 (en) * 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001232175B2 (en) * 2000-03-03 2005-07-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
CA2464309A1 (en) 2003-05-01
HUP0600235A3 (en) 2008-04-28
US20050043409A1 (en) 2005-02-24
ATE381930T1 (de) 2008-01-15
RU2333754C2 (ru) 2008-09-20
EP1441714A2 (en) 2004-08-04
IL161462A0 (en) 2004-09-27
PT1441714E (pt) 2008-03-10
ES2295428T3 (es) 2008-04-16
NZ552335A (en) 2008-11-28
KR20040048992A (ko) 2004-06-10
DE60224299D1 (de) 2008-02-07
HK1068261A1 (en) 2005-04-29
MXPA04003878A (es) 2004-07-08
DK1441714T3 (da) 2008-03-31
CY1108045T1 (el) 2013-09-04
DE60224299T2 (de) 2008-12-11
CA2464309C (en) 2012-01-03
CN1575168A (zh) 2005-02-02
AU2010200433A1 (en) 2010-02-25
AU2006252156A1 (en) 2007-01-18
WO2003035047A3 (en) 2003-10-23
SI1441714T1 (sl) 2008-06-30
EP1441714B1 (en) 2007-12-26
PL369305A1 (en) 2005-04-18
NZ532418A (en) 2007-02-23
WO2003035047A2 (en) 2003-05-01
US20110046190A1 (en) 2011-02-24
CN100506224C (zh) 2009-07-01
KR100954625B1 (ko) 2010-04-27
RU2004116069A (ru) 2005-06-10
HUP0600235A2 (en) 2007-02-28
JP2005506366A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
DE69932183D1 (de) ANWENDUNG VON ZIELGERICHTETEM RADIUM 223 FüR PALLIATIVE UND THERAPEUTISCHE BEHANDLUNG VON KNOCHENKREBS
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
BR0213486A (pt) Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
ATE386029T1 (de) Urokinase-inhibitoren
BRPI0415355A (pt) triarilimidazóis
BRPI0411237A (pt) método para tratamento da esquizofrenia, e, usos de um agente antipsicótico, e de asenapina
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
BR0310027A (pt) Métodos de empregar uma combinação de uma 3-heteroaril-2-indolinona e um inibidor de ciclooxigenase-2 para o tratamento de neoplasia
BG108033A (bg) Използване на 2-амино-1-(4-хидрокси-2-метансулфонамидофенил) етанол за лечение на инконтиненция
ECSP034516A (es) Compuestos de pirazol utiles como inhibidores de protein quinasa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/00; A61P 35/00, 43/00

Ipc: A61K 31/00 (2011.01), A61P 35/00 (2011.01), A61P 4

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI